Modular Medical (MODD)announced the validation of its Pivot controller line, a critical milestone in preparing for the commercial launch of its Pivot patch pump targeted for Q1 2026. The Pivot controller line validation further demonstrates manufacturing readiness for high-volume production, positioning Modular Medical to meet the growing demand in the diabetes treatment market for advanced technology.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MODD:
- Modular Medical announces ‘ongoing progress’ to obtain CE Mark
- Modular Medical appoints David Bosshard as head of international operations
- Modular Medical announces exercise of warrants for $4.4M in proceeds
- Modular Medical Announces Strategic Warrant Exercise Agreement
- Modular Medical receives IRB approval for Pivot system feasability study